Roche Holding AG (OTCMKTS:RHHBY) Short Interest Update

Roche Holding AG (OTCMKTS:RHHBY) saw a significant decline in short interest in the month of February. As of February 13th, there was short interest totaling 2,782,461 shares, a decline of 40.6% from the January 29th total of 4,684,288 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 5,239,296 shares, the short-interest ratio is presently 0.5 days. Based on an average daily trading volume, of 5,239,296 shares, the short-interest ratio is presently 0.5 days. Approximately 0.0% of the shares of the company are sold short.

Institutional Trading of Roche

Several large investors have recently modified their holdings of RHHBY. Curio Wealth LLC acquired a new stake in Roche during the 3rd quarter valued at $25,000. Oakworth Capital Inc. acquired a new position in shares of Roche in the third quarter valued at approximately $57,000. First Horizon Advisors Inc. lifted its stake in shares of Roche by 81.2% during the 2nd quarter. First Horizon Advisors Inc. now owns 1,843 shares of the company’s stock worth $75,000 after purchasing an additional 826 shares during the period. Salomon & Ludwin LLC boosted its holdings in shares of Roche by 256.6% during the third quarter. Salomon & Ludwin LLC now owns 2,853 shares of the company’s stock worth $129,000 after purchasing an additional 2,053 shares during the last quarter. Finally, Atlas Capital Advisors Inc. purchased a new stake in shares of Roche in the fourth quarter valued at $192,000.

Roche Trading Up 0.9%

Shares of OTCMKTS:RHHBY opened at $59.55 on Friday. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.38 and a quick ratio of 1.12. The business’s 50 day simple moving average is $55.49 and its 200-day simple moving average is $47.97. Roche has a 12 month low of $34.75 and a 12 month high of $60.85.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on RHHBY shares. Citigroup began coverage on Roche in a report on Tuesday, January 27th. They issued a “buy” rating for the company. JPMorgan Chase & Co. upgraded shares of Roche from an “underweight” rating to a “neutral” rating in a research note on Monday, December 8th. Barclays raised shares of Roche from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, January 6th. The Goldman Sachs Group upgraded shares of Roche from a “sell” rating to a “hold” rating in a research note on Thursday, January 15th. Finally, Deutsche Bank Aktiengesellschaft upgraded Roche from a “sell” rating to a “hold” rating in a research note on Tuesday, November 11th. Four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $57.00.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.